APOE and tauopathy: Taken together, these findings indicate that HMGB1 plays an essential role in the pathogenic mechanism of APOE4-promoted gliosis and subsequent degeneration and that HMGB1 inhibitors represent a promising therapeutic agent to combat APOE4-driven AD and other tauopathies.